Study of QTX-2101 for adults with a type of leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug, QTX-2101, in people with acute promyelocytic leukemia (APL) that is low- or intermediate-risk. The study aims to see if the drug works and is safe for those who qualify.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 70 years old.
- You must have been diagnosed with acute promyelocytic leukemia (APL) through genetic testing.
- Your APL must be classified as low- or intermediate-risk.
- You need to be willing to follow the study schedule, including visits, treatments, lab tests, and contraception rules.
- You should not have serious heart rhythm problems, leukemia in the brain, severe infections, or other major medical conditions that could make the study unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a treatment approach for children and teens newly diagnosed with acute promyelocytic leukemia (APL) that is confirmed by a specific lab genetic change. It may help improve outcomes, but it requires meeting several safety and test-confirmation criteria.
This trial studies how well a combination of tretinoin (ATRA) and arsenic trioxide (ATO)—with or without another antibody-like drug called gemtuzumab—treats people with newly diagnosed acute promyelocytic leukemia (APL). The goal is to see if these medicines work better together and are safe.
This trial tests a combination of oral arsenic and ATRA for people newly diagnosed with acute promyelocytic leukemia (APL). It aims to see if this drug combo can treat the disease effectively without standard chemotherapy.
This trial is comparing an oral (pill) form of arsenic trioxide to the standard IV (drip) form. If you have already completed initial therapy for your type of leukemia and are in remission, this study could help you take your medicine as a pill instead of through a needle.
This study looks at how well first-time treatment with ATO plus ATRA works in adults with acute promyelocytic leukemia (APL). It mainly checks treatment results in real life, including whether patients reach “molecular remission” (very deep disease control).
This trial studies whether a combination medicine (ATO plus ATRA) is safe and works better in people with a specific type of AML (acute myeloid leukemia) caused by an NPM1 mutation. You would join only after your leukemia has reached remission, meaning the active leukemia has cleared after initial treatment.
Hear when a new Acute Promyelocytic Leukemia With PML-RARA trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.